228 related articles for article (PubMed ID: 20418240)
1. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
Buitenkamp TD; Mathôt RA; de Haas V; Pieters R; Zwaan CM
Haematologica; 2010 Jul; 95(7):1106-13. PubMed ID: 20418240
[TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.
Garré ML; Relling MV; Kalwinsky D; Dodge R; Crom WR; Abromowitch M; Pui CH; Evans WE
J Pediatr; 1987 Oct; 111(4):606-12. PubMed ID: 2958611
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
6. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
7. Vincristine pharmacokinetics in children with Down syndrome.
Lönnerholm G; Frost BM; Söderhäll S; de Graaf SS
Pediatr Blood Cancer; 2009 Jan; 52(1):123-5. PubMed ID: 18615507
[TBL] [Abstract][Full Text] [Related]
8. Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
Bohnstedt C; Taskinen M; Zeller B; Björgvinsdóttir H; Hafsteinsdottir S; Schmiegelow K
J Pediatr Hematol Oncol; 2009 Jan; 31(1):79-80. PubMed ID: 19125098
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.
Hefti E; Blanco JG
J Pediatr Hematol Oncol; 2016 May; 38(4):283-7. PubMed ID: 26907658
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
[TBL] [Abstract][Full Text] [Related]
11. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
12. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
14. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
15. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
16. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
17. Down syndrome and acute lymphoblastic leukaemia.
Whitlock JA
Br J Haematol; 2006 Dec; 135(5):595-602. PubMed ID: 17054672
[TBL] [Abstract][Full Text] [Related]
18. [Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].
Zhang CY; Gu J; Li YZ; Lu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):106-10. PubMed ID: 18315911
[TBL] [Abstract][Full Text] [Related]
19. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Oosterom N; Dirks NF; Heil SG; de Jonge R; Tissing WJE; Pieters R; van den Heuvel-Eibrink MM; Heijboer AC; Pluijm SMF
Support Care Cancer; 2019 Jan; 27(1):183-190. PubMed ID: 29922939
[TBL] [Abstract][Full Text] [Related]
20. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
